LTPHClinical Trials•businesswire•
Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial
Sentiment:Neutral (60)
Summary
(LTPH) DALLAS--(BUSINESS WIRE)--Type C Meeting for LP-184/STAR-001
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 3, 2025 by businesswire